Ronald C Renaud JR insider trades: Cerevel Therapeutics Holdings (CERE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ronald reports to the SEC
and 5 more companies
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 3, 2023 | CERE | ↑ Buy | 83,857 | $23.96 | $2.0M | By Trust | Aug 7, 2023 (4d) |
| Sep 14, 2021 | TBIO | ↓ Sell | 503,231 | $38.00 | $19.1M | Direct | Sep 14, 2021 (0d) |
| Sep 14, 2021 | TBIO | ↓ Sell | 409,913 | $38.00 | $15.6M | By Ronald Renaud 2014 Irrevocable Family | Sep 14, 2021 (0d) |
| Sep 14, 2021 | TBIO | ↓ Sell | 40,909 | $38.00 | $1.6M | By Ronald C. Renaud, Jr. Trust - 2007 | Sep 14, 2021 (0d) |
| Dec 2, 2014 | AKBA | ↑ Buy | 5,000 | $11.92 | $60K | Direct | Dec 2, 2014 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Ronald C Renaud JR's insider trades
Ronald C Renaud JR is President & CEO at Cerevel Therapeutics Holdings (CERE). Since Dec 2, 2014, Ronald has reported 2 open-market purchases worth $2.1M and 3 sales worth $36.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (39 filings), option exercises (6 filings), shares returned to the company (2 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CERE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.